Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

clude patients for whom treatment is begun less than or equal to 6 weeks after diagnosis and in children 8 -11 years old.  In the coming months, MacroGenics will be exploring possible pathways forward for continued development of teplizumab."

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Insulin is a hormone that is needed to convert sugar (glucose), starches and other food into energy needed for daily life. People with type 1 diabetes must take multiple injections of insulin daily or continually infuse insulin through a pump to manage their blood glucose levels.

Type 1 diabetes, previously known as juvenile diabetes, usually strikes in childhood, adolescence, or young adulthood, but lasts for a lifetime. Of the nearly 24 million Americans who have diabetes, as many as 3 million may have type 1.

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance.  MacroGenics retains full worldwide rights to teplizumab.

About MacroGenics, Inc.    

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is b
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... 2014 These vanadium reserves are mostly ... Around 151,000 tons of vanadium were produced globally in ... usage increased at 6.7% AAGR during the period from ... industry, being the largest consumer, accounted for more than ... titanium-vanadium alloy and the chemical industry. , View Full ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX ... cosmetic brand Juvéderm. Voluma XC treats volume loss in ... at Hendrick is pleased to be able to offer ... its clients. , Voluma is the first and only ... the mid-face and cheek area. This non-invasive treatment targets ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- New research warns parents that buying ... at risk. Nearly half of teen drivers killed in the ... at least 11 years old and often lacked important safety features ... percent of teen drivers killed in crashes were in cars at ... 10 years old, 31 percent were in cars 11 to 15 ...
(Date:12/19/2014)... News) -- All children should have their eyesight checked ... year, eye experts say. The new vision-screening guidelines ... the U.S. National Center for Children,s Vision Health. ... require screening for eye problems, particularly vision issues ... eye") and strabismus (a disorder of eye alignment). ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Preschoolers Need Eye Screening, Experts Say 2
... making music is what helps relieves his tensions. The ... battle with estranged wife Heather Mills insisted that his ... ,"I don't see it as anything to do ... The singer, songwriter and multi-instrumentalist whose latest album, 'Memory ...
... With its emergency health care services available across most of ... initiative of Satyam Foundation, plans to cover the entire ... country in the next two years. ,EMRI, which ... a population of 65 million in 19 districts. It aims ...
... be creeping up slowly and has touched almost 12%, which ... recorded in 1992. This was reported on Thursday by the ... that if the trend continues, the nation could surpass the ... ,From 1969 until 1992, the rate of accidental deaths ...
... and KENILWORTH, N.J., Centocor, Inc. and Schering-Plough Corporation ... has approved a new indication for REMICADE(R) ... Crohn's disease (CD) in pediatric patients aged 6 ... conventional therapy including a corticosteroid, an immunomodulator and ...
... per patient could spare 30 millions poor people, many ... epilepsy, a new study released Friday has found . ... the developing world go without any treatment whatsoever because ... impede the terrible seizures associated with the illness. ...
... 15 million dollars worth of anti-retroviral drugs from the ... and AIDS, officials announced . Under the deal, the ... for 40,000 people as well as HIV rapid test ... Parirenyatwa commended the donation by the US government, which ...
Cached Medicine News:Health News:EMRI to Expand Emergency Care Services Throughout India 2Health News:The Rate of Accident Deaths Much Higher 2Health News:Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease 2Health News:Small Change Could Stop Epilepsy Seizures for Millions 2Health News:Zimbabwe Receives 15m Dollars of AIDS Drugs from US 2
Carbo-Seal Valsalva AAP is the first valved graft to replicate the natural Sinus of Valsalva, encouraging the natural formation of systolic vortices....
Current annuloplasty rings and bands are designed for symmetric dilatation. The IMR ETlogix ring is the first asymmetric ring designed to treat asymmetric dilatation....
PremierEdge™ Stab Knives - 30°....
Lacrimal Intubation Set w/Retrieval Device. Size: Probes 23g x 4-1/4"....
Medicine Products: